Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs

Leukemia Research

Volumn 24, Issue 1, 2000, Pages 1-9

  Niitsu, Nozomi ^a,b   Umeda, Masanori ^b   Honma, Yoshio ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

2' Deoxycoformycin; Ara A; Cladribine; Differentiation; Fludarabine; Human myelomonocytic leukemia

Indexed keywords

CLADRIBINE; CYTARABINE; DEOXYADENOSINE DERIVATIVE; DIHYDROXYCOLECALCIFEROL; FLUDARABINE; PENTOSTATIN; VIDARABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CONCENTRATION RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONOCYTIC LEUKEMIA; MYELOID LEUKEMIA; PRIORITY JOURNAL;

ACUTE DISEASE; ADENOSINE DEAMINASE; ANTIMETABOLITES, ANTINEOPLASTIC; CALCITRIOL; CELL DIFFERENTIATION; CLADRIBINE; DEOXYADENOSINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; MONOCYTES; NEOPLASM PROTEINS; PENTOSTATIN; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR STEM CELLS; U937 CELLS; VIDARABINE;

EID: 0033990705     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00143-5     Document Type: Article

References (31)

1. Huang M., Ye Y., Chen S., Chai J., Lu J., Lin Z., Gu L., Wang Z. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 72:1988;567.
2. Degos L., Dombret H., Chomienne C., Daniel M.-T., Miclea J.-M., Chastang C., Castaigne S., Fenaux P. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 85:1995;2643.
3. Ohno R., Naoe T., Hirano M., Kobayashi M., Hirai H., Tubaki K., Oh H. The Leukemia Study Group of the Ministry of Health and Welfare, Treatment of myelodysplastic syndromes with all-trans retinoic acid. Blood. 81:1993;1152.
4. Collins S.J., Bonder R., Ting R., Gallo R.C. Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by compounds which induce differentiation of murine leukemia cells. Int. J. Cancer. 25:1980;213.
5. Plunkett W., Gandhi V. Pharmacokinetics of arabinosylcytosine. J. Infus. Chemother. 2:1992;169.
6. Montgomery J.A., Clayton S.D., Shortnacy A.T., Hewson K. An improved procedure for the preparation of 9-(-D-arabinofuranosyl-2-fluoroadenine. J. Heterocyclic. Chem. 16:1979;157.
7. Brockman R.W., Cheng Y.-C., Schabel F.M., Montgomery J.A. Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res. 40:1980;3610.
8. Simon L.N., Bauer R.J., Tolman R.L., Robins R.K. Calf intestine adenosine deaminase. Substrate specificity. Biochemistry. 9:1970;573.
9. O'Brien S., Kantarjian H., Beran M., Smith T., Koller C., Estey E., Robertson L.E., Lerner S., Keating M. Results of fludarabine- and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 82:1993;1695.
10. Juliusson G., Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocytic count. J. Clin. Oncol. 11:1993;679.
11. Niitsu N., Umeda M., Honma Y. Induction of differentiation of human myeloid leukemia cells by 2′-deoxycoformycin in combination with 2′-deoxyadenosine. Biochem. Biophys. Res. Commun. 238:1997;100.
12. Makishima M., Kanatani Y., Yamamoto-Yamaguchi Y., Honma Y. Enhancement of activity of 1α,25-dihydroxyvitamin D3 for growth inhibition and differentiation induction of human myelomonocytic leukemia cells by tretinoin tocoferil, an α-tocopherol ester of all-trans retinoic acid. Blood. 87:1996;3384.
13. Miyoshi H., Ohki M., Nakagawa T., Honma Y. Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with a t(8;21) chromosome translocation. Leuk. Res. 21:1997;45.
14. Honma Y., Okabe-Kado J., Hozumi M., Uehara Y., Mizuno S. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res. 49:1989;331.
15. Niitsu N., Yamamoto-Yamaguchi Y., Miyoshi H., Shimizu K., Ohki M., Umeda M., Honma Y. AML1a but not AML1b inhibits erythroid differentiation induced by sodium butyrate and enhances the megakaryocytic differentiation of K562 leukemia cells. Cell. Growth. Differ. 8:1997;319.
16. Berenbaum M.C. What is synergy? Pharmacol. Rev. 41:1989;93.
17. Makishima M., Okabe-Kado J., Honma Y. Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1α-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea. Br. J. Cancer. 77:1998;33.
18. Abe E., Miyaura C., Sakagami H., Takeda M., Konno K., Yamazaki T., Yoshiki S., Suda T. Differentiation of mouse myeloid leukemia cells induced by 1α,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA. 78:1981;4990.
19. Miyaura C., Abe E., Kuribayashi T., Tanaka H., Konno K., Nishii Y., Suda T. 1α,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem. Biophys. Res. Commun. 102:1981;937.
20. Honma Y., Hozumi M., Abe E., Konno K., Fukushima M., Hata S., Nishii Y., DeLuca H.F. 1a,25-dihydroxyvitamin D3 and 1a-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc. Natl. Acad. Sci. USA. 80:1983;201.
21. Piro L.D., Carrera C.J., Carson D.A. Lasting remissions in hairycell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New Engl. J. Med. 322:1990;1117.
22. Testa U., Grignani F., Barberi T., Fagioli M., Masciulli R., Ferrucci P.F., Seripa D., Camagna A., Alcalay M., Pelicci P.G., Peschle C. PML/RARα+U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3. Cancer Res. 54:1994;4508.
23. Makishima M., Honma Y., Hozumi M., Sampi K., Hattori M., Ishikawa I., Ogura H., Motoyoshi K. Effects of novel uracil analogs on proliferation and differentiation of human myeloid leukemia cells. Exp. Hematol. 20:1992;879.
24. Kanatani Y., Makishima M., Ishikawa I., Ogasawara Y., Kawahara N., Motoyoshi K., Nagata N., Honma Y. A novel uracil analog, 6-chloro-5-(2-propenyl) uracil, preferentially enhances growth inhibition and differentiation of myeloid leukemia cells induced by 1(,25-dihydroxyvitamin D3. Exp. Hematol. 26:1998;198.
25. Agarwal R.P. Pharmacology of 2′-deoxycoformycin and vidarabine. Cancer Treat. Symp. 2:1984;17.
26. Miser J.S., Roloff J., Blatt J., Reaman G.H., Krailo M.D., Hammond G.D. Lack of significant activity of 2′-deoxycoformycin alone or in combination with adenine arabinoside in relapsed childhood acute lymphoblastic leukemia. Am. J. Clin. Oncol. (CCT). 15:1992;490.
27. Malspeis L., Weinrib A.B., Staubus A.E., Grever M.R., Balcerzak S.P., Neidhart J.A. Clinical pharmacokinetics of 2′-deoxycoformycin. Cancer Treat. Symp. 2:1984;7.
28. Kinkel A.W., Buchanan R.A. Human pharmacology. Pavan-Langston D., Buchanan R.A., Alford C.A. Jr Adenine Arabinoside: An Antiviral Agent. 1975;197 Raven Press, New York.
29. 3: in vivo and in vitro effects on human preleukemic and leukemia cells. Cancer Treat Rep 1985;69:1399.
30. Tallman M.S., Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood. 86:1995;2463.
31. Marks R.S., Richardson R.L., Reid J.M., Bagniewski P.G., Ames M.M. A phase I and pharmacologic study of 2-chlorodeoxyadenosine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 13:1994;416.